Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Ruhstaller T, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018; 29:1386-1393.
Jun 1, 2018
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Jun 1, 2018
Ann Oncol 2018; 29:1386-1393
Ruhstaller Thomas, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S C, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J R, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch
more
